{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:50:07Z","timestamp":1761058207531},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1097\/00000441-200502000-00007","type":"journal-article","created":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T09:01:06Z","timestamp":1107248466000},"page":"95-98","source":"Crossref","is-referenced-by-count":8,"title":["Intravenous Immunoglobulin for Treatment of Toxic Epidermal Necrolysis"],"prefix":"10.1016","volume":"329","author":[{"given":"Maher","family":"Nasser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faris","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ora","family":"Bitterman-Deutsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/00000441-200502000-00007_bb0005","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2133.1956.tb12766.x","article-title":"Toxic epidermal necrolysis: an eruption resembling scalded skin","volume":"68","author":"Lyell","year":"1956","journal-title":"Br J Dermatol"},{"key":"10.1097\/00000441-200502000-00007_bb0010","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe cutaneous adverse reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1097\/00000441-200502000-00007_bb0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens- Johnson syndrome, and erythema multiform","volume":"129","author":"Bastuji-Gorin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1097\/00000441-200502000-00007_bb0020","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1097\/00000441-200502000-00007_bb0025","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004630-200021030-00004","article-title":"A 10-year experience with toxic epidermal necrolysis","volume":"21","author":"Schulz","year":"2000","journal-title":"J Burn Care Rehabil"},{"key":"10.1097\/00000441-200502000-00007_bb0030","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reaction to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1097\/00000441-200502000-00007_bb0035","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archderm.1984.01650420031010","article-title":"Toxic epidermal necrolysis: granulocytic leukopenia as a prognostic indicator","volume":"120","author":"Westly","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1097\/00000441-200502000-00007_bb0040","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0305-4179(95)00140-9","article-title":"Toxic epidermal necrolysis in a burn centre: a 6-year review","volume":"22","author":"Khoo","year":"1996","journal-title":"Burns"},{"key":"10.1097\/00000441-200502000-00007_bb0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1097\/00000441-200502000-00007_bb0050","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/00006534-199809020-00014","article-title":"Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center","volume":"102","author":"McGee","year":"1998","journal-title":"Plast Reconstr Surg"},{"key":"10.1097\/00000441-200502000-00007_bb0055","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00004630-199601000-00008","article-title":"Experience with toxic epidermal necrolysis treated in a burn center","volume":"17","author":"Yarbrough","year":"1996","journal-title":"J Burn Care Rehabil"},{"key":"10.1097\/00000441-200502000-00007_bb0060","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1001\/jama.1987.03390160057026","article-title":"Toxic epidermal necrolysis: a step forward in treatment","volume":"257","author":"Heimbach","year":"1987","journal-title":"JAMA"},{"key":"10.1097\/00000441-200502000-00007_bb0065","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1365-4362.1992.tb04238.x","article-title":"Toxic epidermal necrolysis","volume":"31","author":"Parsons","year":"1992","journal-title":"Int J Dermatol"},{"key":"10.1097\/00000441-200502000-00007_bb0070","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJM198109243051302","article-title":"Predisposition to phenytoin hepatotoxicity assessed in vitro","volume":"305","author":"Spielberg","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1097\/00000441-200502000-00007_bb0075","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-105-2-179","article-title":"Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity","volume":"105","author":"Shear","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1097\/00000441-200502000-00007_bb0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1097\/00000441-200502000-00007_bb0085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","article-title":"Analysis of intravenous immunoglobulin for treatment of toxic epidermal necrolysis using SCORTEN","volume":"1398","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1097\/00000441-200502000-00007_bb0090","first-page":"267","article-title":"Hyperbaric oxygen treatment of toxic epidermal necrolysis","volume":"38","author":"Ruocco","year":"1986","journal-title":"Cutis"},{"key":"10.1097\/00000441-200502000-00007_bb0095","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1177\/039139889101401006","article-title":"Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN)","volume":"14","author":"Sakellariou","year":"1991","journal-title":"Int J Artif Organs"},{"key":"10.1097\/00000441-200502000-00007_bb0100","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2133.1996.tb01167.x","article-title":"Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis","volume":"135","author":"Goulden","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1097\/00000441-200502000-00007_bb0105","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0190-9622(90)70333-D","article-title":"Toxic epidermal necrolysis (Lyell syndrome)","volume":"23","author":"Roujeau","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1097\/00000441-200502000-00007_bb0110","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Ann Surg"},{"key":"10.1097\/00000441-200502000-00007_bb0115","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/archderm.1995.01690170046006","article-title":"Metabolic predisposition to cutaneous adverse drug reactions: role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants","volume":"131","author":"Wolkenstein","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1097\/00000441-200502000-00007_bb0120","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/archderm.1992.01680110060006","article-title":"Immunopathology of toxic epidermal necrolysis, keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases","volume":"128","author":"Villada","year":"1992","journal-title":"Arch Dermatol"},{"key":"10.1097\/00000441-200502000-00007_bb0125","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archderm.1993.01680250078010","article-title":"Cutaneous T-cell recruitment in toxic epidermal necrolysis: further evidence of CD8+ lymphocyte involvement","volume":"129","author":"Correia","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1097\/00000441-200502000-00007_bb0130","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1001\/archderm.1987.01660330077013","article-title":"The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell syndrome)","volume":"123","author":"Guillaume","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1097\/00000441-200502000-00007_bb0135","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0140-6736(98)05418-X","article-title":"Risk of Stevens- Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case\u2013control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions","volume":"353","author":"Rzany","year":"1999","journal-title":"Lancet"},{"key":"10.1097\/00000441-200502000-00007_bb0140","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of cd35 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1097\/00000441-200502000-00007_bb0145","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1523-1747.2000.00037.x","article-title":"Death receptors in cutaneous biology and disease","volume":"115","author":"Werhrli","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1097\/00000441-200502000-00007_bb0150","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s001340050492","article-title":"Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study","volume":"23","author":"Lebargy","year":"1997","journal-title":"Intensive Care Med"},{"key":"10.1097\/00000441-200502000-00007_bb0155","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1177\/000992289903800709","article-title":"Long-term ocular complication of Stevens- Johnson syndrome","volume":"38","author":"Lehman","year":"1999","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1097\/00000441-200502000-00007_bb0160","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00004630-199111000-00015","article-title":"Treatment of toxic epidermal necrolysis by burn units: another market or another threat?","volume":"12","author":"Jordan","year":"1991","journal-title":"J Burn Care Rehabil"},{"key":"10.1097\/00000441-200502000-00007_bb0165","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1056\/NEJM198511283132205","article-title":"Burns","volume":"313","author":"Demling","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1097\/00000441-200502000-00007_bb0170","first-page":"27","article-title":"Effectiveness of early therapy with corticosteroids in Stevens Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis","volume":"73","author":"Patterson","year":"1994","journal-title":"Ann Allergy"},{"key":"10.1097\/00000441-200502000-00007_bb0175","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/000992289503400109","article-title":"Treatment of Steven-Johnson syndrome with pooled human intravenous immune globulin","volume":"34","author":"Moudgil","year":"1995","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1097\/00000441-200502000-00007_bb0180","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0190-9622(08)80969-3","article-title":"Efficacy of cyclophosphamide in toxic epidermal necrolysis: clinical and pathophysiologic aspects","volume":"25","author":"Heng","year":"1991","journal-title":"J Am Acad Dermatol"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915339136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915339136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T14:30:59Z","timestamp":1586097059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915339136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S0002962915339136"],"URL":"https:\/\/doi.org\/10.1097\/00000441-200502000-00007","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2005,2]]}}}